BofA downgraded Cencora to Neutral from Buy with a price target of $245, down from $275. Industry growth is normalizing and the competitive dynamics are shifting following years of stable end markets in drug distribution and tailwinds from COVID, the analyst tells investors. In that context, the firm sees some risk to double-digit EPS growth over the next view years and expects some downward pressure on the multiple as investors reassess the current environment, BofA says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Election 2024: Where To Put Your Money Ahead of the Vote
- Cencora price target lowered to $283 from $287 at Baird
- Cencora Announces EPS Forecast and Evernorth Contract Renewal
- TD Cowen sees ‘minimal’ impact to Cencora FY25 EPS from Cigna change
- Cencora Enhances Governance and Executive Compensation Structures